← Leaderboards
Benjamin F Cravatt
Scripps Research Institute
$59,198,934
Attributed
$75,191,674
Total exposure
27
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$85,769,261 · 28
By mechanism
R01$28,014,587 · 11
P01$17,304,619 · 6
RC2$11,206,792 · 2
R35$8,619,965 · 1
U19$7,374,349 · 1
R24$4,718,329 · 1
Top collaborators
- Enrique Saez9 shared
- Louis Daniel Scampavia8 shared
- Aron H Lichtman6 shared
- Dale L Boger5 shared
- Thomas J. Kodadek5 shared
- Paul S Mischel5 shared
- Li Ye3 shared
- Loren H Parsons2 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- Peiqing Sun$10,120,095
Others in their field
Top investigators on “Proteomics”
- David Heimbrook · Leidos Biomedical Research, Inc.$318,825,229
- Stanley M Lemon · Univ Of North Carolina Chapel Hill$110,612,005
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Gaetano T Montelione · Rutgers The St Univ Of Nj New Brunswick$70,176,616
- Rolf Apweiler · European Molecular Biology Laboratory$67,677,991
- Daniel Ernest Ford · Johns Hopkins University$67,257,868
Research focus
ProteomicsEnzymesProteinsCellsPlayBiologicalInhibitor/AntagonistActivity-Based Protein ProfilingProgramsTechnologyBaseInnovationMolecularProteomeIn VivoSignal TransductionMetabolicMalignant NeoplasmsBiochemicalPathway InteractionsPhysiologicalMapsCommunitiesSmall Molecule
Grant awards (145)
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$916,320
R35 · FY2025 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$670,026
R01 · FY2025 · CA
A platform to identify in vivo targets of covalent cancer drugs in 3D tissues$458,160
R33 · FY2025 · CA
eDyNAmiC - SCRIPPS$407,188
OT2 · FY2025 · CA · contact PI
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$1,102,950
R35 · FY2024 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$641,594
R01 · FY2024 · CA
A platform to identify in vivo targets of covalent cancer drugs in 3D tissues$435,254
R33 · FY2024 · CA
eDyNAmiC - SCRIPPS$350,496
OT2 · FY2024 · CA · contact PI
RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins$1,729,091
U19 · FY2023 · AI · contact PI
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$1,137,779
R35 · FY2023 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$666,928
R01 · FY2023 · CA
A platform to identify in vivo targets of covalent cancer drugs in 3D tissues$450,690
R33 · FY2023 · CA
eDyNAmiC - SCRIPPS$334,504
OT2 · FY2023 · CA · contact PI
RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins$1,672,390
U19 · FY2022 · AI · contact PI
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$1,137,779
R35 · FY2022 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$671,855
R01 · FY2022 · CA
eDyNAmiC - SCRIPPS$332,321
OT2 · FY2022 · CA · contact PI
Chemoproteomic Identification and Therapeutic Validation of Proteins of Metabolic Significance$1,640,587
RC2 · FY2021 · DK
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$1,161,000
R35 · FY2021 · CA · contact PI
RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins$773,905
U19 · FY2021 · AI · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$696,619
R01 · FY2021 · CA
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$486,911
R01 · FY2021 · DA · contact PI
Chemoproteomic Identification and Therapeutic Validation of Proteins of Metabolic Significance$1,640,587
RC2 · FY2020 · DK
RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins$1,456,671
U19 · FY2020 · AI · contact PI
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$1,161,000
R35 · FY2020 · CA · contact PI
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$486,911
R01 · FY2020 · DA · contact PI
RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins$1,742,292
U19 · FY2019 · AI · contact PI
Chemoproteomic Identification and Therapeutic Validation of Proteins of Metabolic Significance$1,640,587
RC2 · FY2019 · DK
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$1,126,170
R35 · FY2019 · CA · contact PI
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$486,911
R01 · FY2019 · DA · contact PI
Chemoproteomic Identification and Therapeutic Validation of Proteins of Metabolic Significance$1,640,587
RC2 · FY2018 · DK
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability$876,967
R35 · FY2018 · CA · contact PI
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$536,462
R01 · FY2018 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$475,796
R01 · FY2018 · CA · contact PI
High-Throughput screening for inhibitors of neuroinflammatory lipid production$340,116
R01 · FY2018 · NS · contact PI
Chemical Approaches for Activity-Based Proteomics$294,818
R37 · FY2018 · CA · contact PI
Chemoproteomic Identification and Therapeutic Validation of Proteins of Metabolic Significance$1,687,337
RC2 · FY2017 · DK
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$610,184
R01 · FY2017 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$475,796
R01 · FY2017 · CA · contact PI
High-Throughput screening for inhibitors of neuroinflammatory lipid production$382,717
R01 · FY2017 · NS · contact PI
Chemical Approaches for Activity-Based Proteomics$294,818
R37 · FY2017 · CA · contact PI
Identification and Therapeutic Valiation of Adipocyte Serine Hydrolases of Metab$1,384,096
R24 · FY2016 · DK
Chemoproteomic methods for serine hydrolase inhibitor development$525,195
R01 · FY2016 · DA · contact PI
High-Throughput screening for inhibitors of neuroinflammatory lipid production$493,260
R01 · FY2016 · NS · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$469,316
R01 · FY2016 · CA · contact PI
Chemical Approaches for Activity-Based Proteomics$294,818
R37 · FY2016 · CA · contact PI
Identification and Therapeutic Valiation of Adipocyte Serine Hydrolases of Metab$1,379,304
R24 · FY2015 · DK
Chemoproteomic methods for serine hydrolase inhibitor development$505,322
R01 · FY2015 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$469,316
R01 · FY2015 · CA · contact PI
Chemical Approaches for Activity-Based Proteomics$294,818
R37 · FY2015 · CA · contact PI
Identification and Therapeutic Valiation of Adipocyte Serine Hydrolases of Metab$1,089,929
R24 · FY2014 · DK
Chemoproteomic methods for serine hydrolase inhibitor development$502,584
R01 · FY2014 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$491,691
R01 · FY2014 · CA · contact PI
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders$480,350
R01 · FY2014 · DA · contact PI
Chemical Approaches for Activity-Based Proteomics$294,818
R37 · FY2014 · CA · contact PI
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (JW)$73,188
R01 · FY2014 · DA · contact PI
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (RO)$41,610
R01 · FY2014 · DA · contact PI
Endocannabinoid Metabolic Enzymes: Structure, Function, In Vivo Inhibition$1,120,904
P01 · FY2013 · DA · contact PI
Identification and Therapeutic Valiation of Adipocyte Serine Hydrolases of Metab$865,000
R24 · FY2013 · DK
Massively Parallel Identification of Protein Ligands$726,031
R01 · FY2013 · GM · contact PI
Functional Studies of Endocannabinoid Metabolizing Enzymes$489,045
P01 · FY2013 · DA · contact PI
Chemoproteomic methods for serine hydrolase inhibitor development$472,757
R01 · FY2013 · DA · contact PI
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders$443,581
R01 · FY2013 · DA · contact PI
Project 3$299,016
P01 · FY2013 · DA · contact PI
Chemical Approaches for Activity-Based Proteomics$295,440
R37 · FY2013 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$253,719
P01 · FY2013 · DA · contact PI
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders$33,950
R01 · FY2013 · DA · contact PI
Endocannabinoid Metabolic Enzymes: Structure, Function, In Vivo Inhibition$1,176,412
P01 · FY2012 · DA · contact PI
Massively Parallel Identification of Protein Ligands$747,843
R01 · FY2012 · GM · contact PI
Functional Studies of Endocannabinoid Metabolizing Enzymes$505,478
P01 · FY2012 · DA · contact PI
Chemoproteomic methods for serine hydrolase inhibitor development$504,995
R01 · FY2012 · DA · contact PI
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders$419,934
R01 · FY2012 · DA · contact PI
Chemical Approaches for Activity-Based Proteomics$317,378
R37 · FY2012 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$264,982
P01 · FY2012 · DA · contact PI
Project 3$257,365
P01 · FY2012 · DA · contact PI
Endocannabinoid Metabolic Enzymes: Structure, Function, In Vivo Inhibition$1,169,156
P01 · FY2011 · DA · contact PI
Massively Parallel Identification of Protein Ligands$747,193
R01 · FY2011 · GM · contact PI
Functional Studies of Endocannabinoid Metabolizing Enzymes$501,638
P01 · FY2011 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$425,482
R01 · FY2011 · CA · contact PI
Chemical Approaches for Activity-Based Proteomics$320,490
R37 · FY2011 · CA · contact PI
Project 3$280,523
P01 · FY2011 · DA · contact PI
Toward a potent and selective inhibitor for every mammalian serine hydrolase$272,965
R01 · FY2011 · DA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$265,713
P01 · FY2011 · DA · contact PI
A Quantitative Proteomics Platform to Characterize the Nicotine-Dependent Brain$1,413,284
RC2 · FY2010 · DA · contact PI
Endocannabinoid Metabolic Enzymes: Structure, Function, In Vivo Inhibition$1,183,378
P01 · FY2010 · DA · contact PI
Massively Parallel Identification of Protein Ligands$760,699
R01 · FY2010 · GM · contact PI
Functional Studies of Endocannabinoid Metabolizing Enzymes$502,089
P01 · FY2010 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$439,287
R01 · FY2010 · CA · contact PI
Chemical Approaches for Activity-Based Proteomics$340,314
R37 · FY2010 · CA · contact PI
Toward a potent and selective inhibitor for every mammalian serine hydrolase$281,408
R01 · FY2010 · DA · contact PI
Project 3$277,967
P01 · FY2010 · DA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$265,953
P01 · FY2010 · DA · contact PI
A Quantitative Proteomics Platform to Characterize the Nicotine-Dependent Brain$1,543,823
RC2 · FY2009 · DA · contact PI
Endocannabinoid Metabolic Enzymes: Structure, Function, In Vivo Inhibition$1,236,161
P01 · FY2009 · DA · contact PI
Massively Parallel Identification of Protein Ligands$774,499
R01 · FY2009 · GM · contact PI
Selectivity/Spec Profiling (California)$529,666
U54 · FY2009 · MH · contact PI
Functional Studies of Endocannabinoid Metabolizing Enzymes$514,867
P01 · FY2009 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$448,723
R01 · FY2009 · CA · contact PI
Chemical Approaches for Activity-Based Proteomics$340,314
R37 · FY2009 · CA · contact PI
Enzymes that Regulate Fatty Acid Amide Function in Vivo$302,634
R01 · FY2009 · DA · contact PI
Project 3$284,953
P01 · FY2009 · DA · contact PI
Toward a potent and selective inhibitor for every mammalian serine hydrolase$284,250
R01 · FY2009 · DA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$260,814
P01 · FY2009 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$88,039
R01 · FY2009 · CA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$87,829
R01 · FY2009 · CA · contact PI
FAAH: Structure, Function, and In Vivo Inhibition$990,122
P01 · FY2008 · DA · contact PI
Selectivity/Spec Profiling (California)$677,079
U54 · FY2008 · MH · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$602,495
R01 · FY2008 · CA · contact PI
Microarray Platform for Profiling Cancer Proteases$368,009
R33 · FY2008 · CA · contact PI
Chemical Approaches for Activity Based Proteomics$323,425
R01 · FY2008 · CA · contact PI
FUNCTIONAL STUDIES OF FAAH$310,936
P01 · FY2008 · DA · contact PI
Enzymes that Regulate Fatty Acid Amide Function in Vivo$302,634
R01 · FY2008 · DA · contact PI
Toward a potent and selective inhibitor for every mammalian serine hydrolase$284,250
R01 · FY2008 · DA · contact PI
FAAH: Structure, Function, and In Vivo Inhibition$968,010
P01 · FY2007 · DA · contact PI
Chemical Probes for Metabolic Pathway Discovery in Human Disease$633,635
R01 · FY2007 · CA · contact PI
Microarray Platform for Profiling Cancer Proteases$361,018
R33 · FY2007 · CA · contact PI
Chemical Approaches for Activity Based Proteomics$320,353
R01 · FY2007 · CA · contact PI
FUNCTIONAL STUDIES OF FAAH$306,010
P01 · FY2007 · DA · contact PI
Enzymes that Regulate Fatty Acid Amide Function in Vivo$304,970
R01 · FY2007 · DA · contact PI
Drug Abuse Related Polymorphism in Fatty Acid Amide Hydrolase$180,509
R21 · FY2007 · DA · contact PI
FAAH: Structure, Function, and In Vivo Inhibition$967,879
P01 · FY2006 · DA · contact PI
Microarray Platform for Profiling Cancer Proteases$371,800
R33 · FY2006 · CA · contact PI
Chemical Approaches for Activity Based Proteomics$329,920
R01 · FY2006 · CA · contact PI
Enzymes that Regulate Fatty Acid Amide Function in Vivo$314,078
R01 · FY2006 · DA · contact PI
FUNCTIONAL STUDIES OF FAAH$313,329
P01 · FY2006 · DA · contact PI
Drug Abuse Related Polymorphism in Fatty Acid Amide Hydrolase$185,900
R21 · FY2006 · DA · contact PI
FAAH: Structure, Function, and In Vivo Inhibition$962,511
P01 · FY2005 · DA
Enzymes that Regulate Fatty Acid Amide Function in Vivo$340,965
R01 · FY2005 · DA
Chemical Approaches for Activity Based Proteomics$337,860
R01 · FY2005 · CA
FUNCTIONAL STUDIES OF FAAH$304,337
P01 · FY2005 · DA
FAAH: Structure, Function, and In Vivo Inhibition$803,054
P01 · FY2004 · DA
Chemical Approaches for Activity Based Proteomics$337,860
R01 · FY2004 · CA
STRUCTURE/FUNCTION STUDIES OF FATTY ACID AMIDE HYDROLASE$324,100
R01 · FY2004 · DA
Enzymes That Regulate Fatty Acid Amide Function In Vivo$289,366
R01 · FY2004 · DA
FUNCTIONAL STUDIES OF FAAH$268,298
P01 · FY2004 · DA
STRUCTURE/FUNCTION STUDIES OF FATTY ACID AMIDE HYDROLASE$324,100
R01 · FY2003 · DA
CHEMICAL APPROACHES FOR ACTIVITY BASED PROTEOMICS$291,690
R01 · FY2003 · CA
Enzymes That Regulate Fatty Acid Amide Function In Vivo$289,366
R01 · FY2003 · DA
STRUCTURE/FUNCTION STUDIES OF FATTY ACID AMIDE HYDROLASE$324,100
R01 · FY2002 · DA
Enzymes That Regulate Fatty Acid Amide Function In Vivo$308,299
R01 · FY2002 · DA
CHEMICAL APPROACHES FOR ACTIVITY BASED PROTEOMICS$291,690
R01 · FY2002 · CA
STRUCTURE/FUNCTION STUDIES OF FATTY ACID AMIDE HYDROLASE$310,275
R01 · FY2001 · DA
CHEMICAL APPROACHES FOR ACTIVITY BASED PROTEOMICS$279,248
R01 · FY2001 · CA
MOLECULAR STUDIES OF THE SLEEP INDUCING LIPID, OLEAMIDE$334,860
R01 · FY2000 · MH
CHEMICAL APPROACHES FOR ACTIVITY BASED PROTEOMICS$272,291
R01 · FY2000 · CA